drugset / Trial / NCT00407199

The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment

NCT00407199

Phase 4 Completed 20 enrolled University of Minnesota AstraZeneca · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This is a pilot study that will focus on the collection of preliminary data to determine the efficacy of quetiapine for individuals with social phobia. We hypothesize that individuals will react with less self-reported anxiety and physiological reactivity in the drug condition than in the placebo condition. If true, this would constitute a strong signal for a significant treatment effect for quetiapine in social phobia. A positive treatment effect in this study would provide rationale for further investigation of the efficacy of quetiapine for cue reactivity for individuals with social phobia. Further study would include increased sample size in order to obtain statistical power and replication of findings. We will utilize the IR formulation of quetiapine.

Timeline

Start
2006-12
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 25 mg

Indications